Double vulnerability of active-NRF2 lung squamous cell carcinoma to NRF2 and TRIM24

dc.contributor.authorSánchez Ortega, Miriam
dc.contributor.authorGarrido Tarrío, Antonio
dc.contributor.authorSanz, Lorena
dc.contributor.authorTorres Pérez, Rafael
dc.contributor.authorHernández, Carmen
dc.contributor.authorGutiérrez Uzquiza, Álvaro
dc.contributor.authorTsao, Ming Sound
dc.contributor.authorCarrera, Ana Clara
dc.date.accessioned2025-07-26T10:14:58Z
dc.date.available2025-07-26T10:14:58Z
dc.date.issued2025
dc.description.abstractLung squamous cell cancer (LUSC) is associated with very poor survival due to the lack of specific treatments. A common genetic alteration in LUSC involves mutations in NFE2L2 (protein named NRF2) or its regulator, KEAP1, resulting in increased activity of the NRF2 transcription factor (TF). This study compares the requirement for activeNRF2 in LUSC cell lines. Although normal-NRF2 cells are more sensitive to oxidative stress, they do not require NRF2 for survival under non-stress conditions, in contrast, LUSC cells with active-NRF2 mutations depend on NRF2 for viability. NRF2 depletion in patient-derived organoid cultures with active-NRF2 as well as in xenografts with active-NRF2 triggers cell death. The focus of this study is to find genes that rescue cell death upon NRF2depletion in active-NRF2 cells. A CRISPRa/dCas9 screening for gene targets capable of rescuing cell survival in these cells identified TRIM24 as a gene whose expression saves cell survival in NRF2-depleted active-NRF2 LUSC cells. Alongside oxidative stress, the lack of TRIM24 selectively contributed to the induction of cell death (apoptosis and ferroptosis) in active-NRF2 LUSC cells. Cells with a high NFE2L2/KEAP1 copy number ratio also undergo cell death. The increase in cell death observed upon TRIM24 depletion involves a reduction of TRIM24/PI3Kα complexes which destabilizes the PI3Kα catalytic subunit. Notably, overexpression of PI3Kα rescues cell survival in TRIM24-depleted active-NRF2 cells. These findings point to novel therapeutic approaches in LUSC.
dc.description.filiationUEM
dc.description.impact33,9 Q1 JCR 2024spa
dc.description.impact9.263 Q1 SJR 2024spa
dc.description.impactNo data IDR 2023spa
dc.description.sponsorshipMinisterio de Ciencia e Innovación (MCIN) (PID2019-106937RB PIA12019; PDC-2022-133912) por el Gobierno de la Comunidad de Madrid (S2020/BMD-7321)
dc.description.sponsorshipComunidad Europea European COST Action CA20121 (BenBedPhar)
dc.description.sponsorshipAsociación Española contra el Cáncer (16035CARR)
dc.description.sponsorshipCanadian Institutes of Health Research FDN-148395
dc.identifier.citationSánchez-Ortega, M., Garrido, A., Sanz, L., Torres Pérez, R., Hernández, C., Gutiérrez Uzquiza, Á., Tsao, M. S. y Carrera, A. C. (2025). Double vulnerability of active-NRF2 lung squamous cell carcinoma to NRF2 and TRIM24. Mol Cancer 24, 197. https://doi.org/10.1186/s12943-025-02401-y
dc.identifier.doi10.1186/s12943-025-02401-y
dc.identifier.issn1476-4598
dc.identifier.urihttps://hdl.handle.net/11268/16047
dc.language.isoeng
dc.peerreviewedSi
dc.relation.publisherversionhttp://doi.org/10.1186/s12943-025-02401-y
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.otherFactor 2 Relacionado con NF-E2
dc.subject.otherNeoplasias pulmonares
dc.subject.sdgGoal 3: Ensure healthy lives and promote well-being for all at all ages
dc.subject.unescoCiencias médicas
dc.subject.unescoInvestigación médica
dc.subject.unescoCáncer
dc.titleDouble vulnerability of active-NRF2 lung squamous cell carcinoma to NRF2 and TRIM24
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication10dac0b2-63a7-4be6-abed-32585380920e
relation.isAuthorOfPublication.latestForDiscovery10dac0b2-63a7-4be6-abed-32585380920e

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Garrido A. Mol Cancer. 2025.pdf
Size:
5 MB
Format:
Adobe Portable Document Format